Loading SUVEN price...
Peers are the listed companies in the exchange's own industry group: Healthcare Research Analytics & Technology. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.
Latest quarterIn the quarter to June 2026 (results filed 6 Aug 2026), sales rose 91.0% from a year earlier to Rs 3.6 cr and the loss was Rs 128 cr against Rs 51.5 cr a year earlier.
- No borrowings at the FY26 balance sheet.
- Reported a loss in FY23 and FY24 and FY26.
- Profit before interest covered interest -1380.5 times in FY26 (Rs 0 cr of interest).
Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.
Over the last 20 results, the share rose on 10 and fell on 10, and moved by 3% or more on 9.
Q1 FY27: results filed 6 Aug 2026. The share went from its close on 5 Aug 2026 to its close on 7 Aug 2026 -2.50%.
Of every Rs 100 of sales in FY26, Rs 4107 went on running costs, Rs 79 on depreciation, Rs 2.8 on interest; the year ended in a loss.
Thin bar: money in (sales plus other income). Thick bar: where it went. Each year is scaled to its own sales, so the bars compare shares, not size.
Per year, compounded, between financial years FY26 and the year named; only spans our filings cover. The faint bar is the latest quarter against the same quarter a year earlier. Earnings per share is not shown: filed figures are not adjusted for bonus issues and splits, so its growth would mislead.
| Measure | FY22 | FY23 | FY24 | FY26 |
|---|---|---|---|---|
| Sales growthSales against the previous financial year. | - | 14.4% | -13.3% | - |
| Operating marginProfit from operations, before depreciation, interest and tax, per Rs 100 of sales. | -1038% | -933% | -1094% | -4007% |
| Net marginProfit after everything, per Rs 100 of sales. | -1034% | -876% | -898% | -3892% |
| ROEProfit as a percentage of shareholders' money (from the March balance sheet). | - | -31.5% | -38.9% | -46.7% |
| ROCEOperating profit as a percentage of all long-term capital, owners' and lenders'. | - | -31.2% | -39.0% | -46.5% |
| Debt to equityBorrowings divided by shareholders' money. Lower is safer. | - | 0.00x | 0.00x | 0.00x |
| Interest coverHow many times operating profit covers the interest bill. Higher is safer. | -243.0x | -393.3x | -529.5x | -1380.5x |
Each row is coloured against this company's own usual level, not against other companies: green is better than its middle year, red worse, plain is close to it. ROE, ROCE and debt rows start once the filings carry a full balance sheet (FY22 at the earliest).
At FY26 it owned Rs 624 Cr of assets. Its owners funded 95% of that, with no borrowings.
From the March balance sheet in the company's annual filing (2026-03-31). Each bar is the full balance sheet; "everything else" is what the filed total leaves after the named lines.
In FY26 the business itself brought in Rs -302 Cr, spent Rs 5 Cr on plant and equipment, and cash fell by Rs 7 Cr over the year.
Full financial year to 2026-03-31, from the company's cash flow statement.
Median rather than average, so one loss-making or one very expensive peer cannot drag the reference. Valuation is shown without a colour verdict: a higher multiple can mean expensive, or faster growth expected, and only you can decide which.
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| APOLLOHOSP Apollo Hospitals Enterprise Limited | 1.13 L cr | 54.0x | 11.9x | 21.8% | 19.5% | 0.57 | 8.2% | +20.6% | 0.26% |
| MAXHEALTH Max Healthcare Institute Limited | 81,266 cr | 56.0x | 7.6x | 13.6% | 12.7% | 0.32 | 16.7% | +16.7% | 0.18% |
| MANIPALHOS Manipal Health Enterprises Limited | 73,581 cr | - | - | - | - | - | - | - | - |
| FORTIS Fortis Healthcare Limited | 55,467 cr | 52.9x | 5.6x | 10.5% | 12.0% | 0.28 | 11.3% | +17.5% | 0.14% |
| NH Narayana Hrudayalaya Ltd. | 33,971 cr | 41.4x | 7.5x | 18.0% | 11.4% | 1.07 | 9.0% | +78.0% | 0.27% |
| ASTERDM Aster DM Quality Care Limited | 33,523 cr | 104.9x | 7.3x | 7.5% | 10.2% | 0.15 | 7.4% | +21.6% | 0.16% |
| MEDANTA Global Health Limited | 32,575 cr | 58.6x | 8.2x | 13.9% | 15.1% | 0.30 | 11.8% | +26.5% | 0.04% |
| LALPATHLAB Dr. Lal Path Labs Ltd. | 31,100 cr | 44.8x | 12.4x | 21.5% | 25.7% | 0.00 | 18.9% | +19.1% | 0.72% |
| KIMS Krishna Institute of Medical Sciences Limited | 28,123 cr | 131.3x | 12.5x | 7.6% | 8.2% | 1.27 | 4.6% | +35.3% | 0.74% |
| AGARWALEYE Dr. Agarwal's Health Care Limited | 15,065 cr | 102.2x | 7.4x | 8.7% | 9.7% | 0.07 | 8.4% | +26.0% | 0.01% |
| SYNGENE Syngene International Limited | 14,527 cr | 65.5x | 3.0x | 4.6% | 8.3% | 0.00 | 6.1% | -15.8% | 0.35% |
| INDGN Indegene Limited | 14,472 cr | 36.3x | 4.6x | 12.8% | 15.4% | 0.00 | 10.5% | +39.7% | 0.33% |
| VIJAYA Vijaya Diagnostic Centre Limited | 14,362 cr | 76.7x | 15.0x | 19.6% | 19.2% | 0.00 | 21.9% | +22.8% | 0.14% |
| RAINBOW Rainbow Childrens Medicare Limited | 11,802 cr | 41.3x | 7.2x | 17.4% | 16.8% | 0.00 | 15.9% | +33.2% | 0.26% |
| METROPOLIS Metropolis Healthcare Limited | 10,989 cr | 22.8x | 7.3x | 13.3% | 15.7% | 0.01 | 11.9% | +16.6% | 0.19% |
| PARKHOSPS Park Medi World Limited | 9,487 cr | - | 4.7x | - | 18.1% | 0.11 | - | - | 0.00% |
| YATHARTH Yatharth Hospital & Trauma Care Services Limited | 8,924 cr | 49.3x | 4.9x | 9.7% | 11.0% | 0.14 | 13.1% | +52.3% | 0.00% |
| HCG Healthcare Global Enterprises Limited | 8,508 cr | 367.6x | 6.4x | 2.4% | 6.9% | 0.65 | 1.3% | +13.4% | 0.00% |
| THYROCARE Thyrocare Technologies Limited | 7,491 cr | 27.6x | 12.8x | 30.0% | 33.6% | 0.00 | 20.1% | +24.3% | 1.98% |
| SUVEN Suven Life Sciences Limited | 6,917 cr | - | 11.7x | - | -46.5% | 0.00 | - | +91.0% | 0.00% |
| NEPHROPLUS Nephrocare Health Services Limited | 6,095 cr | - | 5.5x | - | 13.7% | 0.07 | - | - | 0.00% |
| ARTEMISMED Artemis Medicare Services Limited | 4,547 cr | 40.0x | 4.9x | 12.1% | 13.7% | 0.24 | 10.2% | +12.7% | 0.13% |
| INDRAMEDCO Indraprastha Medical Corporation Limited | 2,750 cr | 20.8x | 3.7x | 25.4% | 30.7% | 0.00 | 12.3% | +11.3% | 1.49% |
| VIMTALABS Vimta Labs Limited | 2,185 cr | 27.7x | 4.8x | 17.4% | 21.2% | 0.01 | 19.0% | +11.8% | 0.20% |
| JLHL Jupiter Life Line Hospitals Limited | 1,658 cr | 8.8x | 1.1x | 12.1% | 13.8% | 0.33 | 12.0% | +18.2% | 0.40% |
| SURAKSHA Suraksha Diagnostic Limited | 1,628 cr | 45.4x | 6.7x | 14.4% | 14.7% | 0.01 | 10.8% | +20.8% | 0.00% |
| KRSNAA Krsnaa Diagnostics Limited | 1,617 cr | 16.8x | 1.6x | 9.9% | 10.6% | 0.55 | 11.9% | +22.1% | 0.55% |
| GKSL Gujarat Kidney And Super Speciality Limited | 1,400 cr | 70.8x | 5.5x | 6.6% | 8.6% | 0.06 | 16.6% | - | 0.00% |
| SHALBY Shalby Limited | 1,240 cr | 32.9x | 1.2x | 3.7% | 7.9% | 0.54 | 3.2% | +11.7% | 0.00% |
| GPTHEALTH GPT Healthcare Limited | 1,066 cr | 22.6x | 4.0x | 17.6% | 16.4% | 0.06 | 9.6% | +17.8% | 1.92% |
| HEALTHX Health X Platform Limited | 857 cr | - | 1.3x | -3.4% | - | - | -1.8% | +49.7% | 0.00% |
| GAUDIUMIVF Gaudium IVF and Women Health Limited | 674 cr | - | 4.4x | - | 23.1% | 0.15 | - | - | 0.00% |
| LOTUSEYE Lotus Eye Hospital and Institute Limited | 236 cr | 1419.5x | 3.9x | 0.2% | 1.1% | 0.19 | 0.3% | +26.2% | 0.00% |
| TAKE TAKE Limited | 154 cr | - | 5.0x | - | 15.4% | 0.00 | - | - | 0.00% |
Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.
Operating margin has gone from -1038.1% to -4007.0% over these years - the share of every rupee of sales kept after running costs, before interest and tax. Full financial years only, so a part-year is never shown as a whole one. Hover any year for its complete figures.
2019 paid Rs 1.50 per share, about Rs 574 on Rs 1 lakh at today's price. Dividends are at the company's discretion and can be cut or skipped.
The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.
Insider trading data unavailable.
Announcements unavailable.
Backtest an equity strategy on real market data, free - no card needed.
Equity price, fundamentals and realized volatility are end-of-day / quarterly from real market data. The option chain (PCR, max pain, expected move, IV, OI) is live from the exchange during market hours; outside them it shows the last session's close. Shareholding, insider trades and announcements are the company's own exchange filings. Analysis only, not investment advice.